Vaxcyte Inc(PCVX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 6:40 PM ET (Korea 10/31 07:40)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -7.71 | Insider Own | 2.29% | Shs Outstand | 157.4M | Perf Week | 2.65% |
| Market Cap | 9.76B | Forward P/E | - | EPS next Y | 21.03% | Insider Trans | -4.46% | Shs Float | 153.8M | Perf Month | 10.67% |
| Enterprise Value | 8.39B | PEG | - | EPS next Q | -2.11 | Inst Own | 105.66% | Short Float | 9.51% | Perf Quarter | 15.88% |
| Income | -1.06B | P/S | - | EPS this Y | -46.14% | Inst Trans | 2.3% | Short Ratio | 7.15 | Perf Half Y | 8.96% |
| Sales | 0.00B | P/B | 3.26 | EPS next 5Y | -4.56% | ROA | -33.03% | Short Interest | 14.62M | Perf YTD | 34.44% |
| Book/sh | 19.05 | P/C | 6.57 | EPS past 3/5Y | -17.82% -26.39% | ROE | -36.51% | 52W High | -31.65% ($90.75) | Perf Year | 38.61% |
| Cash/sh | 9.45 | P/FCF | - | Sales past 3/5Y | - | ROIC | -37.12% | 52W Low | 55.58% ($39.87) | Perf 3Y | 30.29% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -83.87% | Gross Margin | - | Volatility(W/M) | 4.1% 6.63% | Perf 5Y | 165.09% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 3.57 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 5.72 | EPS Q/Q | -60.69% | Profit Margin | - | RSI (14) | 48.81 | Recom | 1.2 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.72 | Sales Q/Q | - | SMA20 | -4.64% ($65.05) | Beta | 1.32 | Target Price | $117.3 |
| Payout | - | Debt/Eq | 0.04 | Earnings | 2026/8/5 | SMA50 | 0.69% ($61.6) | Rel Volume | 0.84 | Prev Close | $62.61 |
| Employees | 507 | LT Debt/Eq | 0.04 | EPS/Sales Surpr. | 4.16% - | SMA200 | 8.75% ($57.04) | Avg Volume(3M) | 2.04M | Price | $62.03 |
| IPO | 2020/6/12 | Option/Short | Yes/Yes | Trades | 12655 | Volume | 1,714,266 | Change | -0.93% |
💉 This is a clinical-stage biotech company developing next-generation vaccines. It uses its proprietary protein synthesis technology to develop next-generation protein-conjugate vaccines targeting bacterial infections such as pneumococcus, aiming to provide broader strain coverage than existing vaccines. As a vaccine/healthcare stock, its share price is driven by results from late-stage clinical candidates and progress in regulatory approval.
Over the past 1 year, roughly in the middle
32% below its 1-year high.
Traded about as much as usual. That is 84% of its average volume.
PCVX has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -46.1% this year.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +165.1%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 105.7%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #26 of 597 in the industry
Based on market cap of $10B.
FAQ
What kind of company is PCVX?
PCVX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of PCVX?
The market cap of PCVX is approximately $9.8B, ranking 936 within its sector.
What is the 52-week high and low for PCVX?
PCVX has recorded a 52-week high of $90.75 and a low of $39.87.
